NCT04970381View on ClinicalTrials.gov

An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE)

NACompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

September 27, 2020

Primary Completion Date

October 30, 2022

Study Completion Date

October 30, 2022

Conditions
Ventricular Mural Thrombosis
Interventions
DRUG

Rivaroxaban

Rivaroxaban: Patients with ventricular mural thrombus in the study receive rivaroxaban anticoagulant therapy for 12 weeks. The dosage of rivaroxaban was typically 20mg once daily, or 15mg once daily if patients were on dual antiplateletagents, or with creatinine clearance of 30-50mL/min.

Trial Locations (1)

100037

Fuwai Hospital, Chinese Academy of Medical Sciences & Pecking Union Medical College, Beijing

All Listed Sponsors
lead

China National Center for Cardiovascular Diseases

OTHER_GOV

NCT04970381 - An Exploratory stuDy of effectIveneSs and Safety of rivarOxaban in Patients With Left VEntricular Thrombus (R-DISSOLVE) | Biotech Hunter | Biotech Hunter